Amgen And Biovitrum AB Expand Diabetes Treatment License
CHICAGO, Feb 13 (Reuters) - Amgen Inc. (AMGN.O: Quote, Profile, Research), the world's largest biotechnology company, and Sweden's Biovitrum AB said on Monday they have expanded their licensing agreement on an experimental treatment for type 2 diabetes and other metabolic disorders.